Status:
RECRUITING
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Lead Sponsor:
Yigeng Cao,MD,PhD
Conditions:
Hematopoietic Stem Cell Transplantation (HSCT)
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
Brief Summary
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau....
Detailed Description
HALO-SCT is a prospective observational patient registry established at Qinghai University Affiliated Hospital, the first HSCT center in the Qinghai-Tibet Plateau. The registry aims to systematically ...
Eligibility Criteria
Inclusion
- Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
- Planned or actual hematopoietic stem cell transplantation (HSCT).
- Provision of signed informed consent.
Exclusion
- Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
- Substance abuse compromising adherence.
- Any condition judged by investigators to jeopardize safety or compliance.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2100
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT07205523
Start Date
September 1 2023
End Date
December 31 2100
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Qinghai University
Xining, Qinghai, China, 810001